Thermo Fisher Scientific is the world leader in serving science. We offer leading next-generation sequencing (NGS) solutions for the study of myeloid and lymphoid malignancy samples, including assays for genomic profiling and clonality detection. Our latest platform can deliver NGS results in as fast as 1 day. As a leading global provider of clinical research services, we enable our customers to accelerate innovation and increase drug development productivity. Learn more at oncomine.com/ash2023